Show notes
Last week, the US FDA and CMS announced the TCET pathway, a landmark program to accelerate insurance coverage for innovative medical devices. This move aims to eliminate the notorious "valley of death" where approved devices fail to secure reimbursement, but it also creates new strategic challenges for MedTech manufacturers.
This episode of MedTech Global Insights dives into the specifics of this new policy. We analyze how it fundamentally changes the commercialization timeline and what companies must do to capitalize on this opportunity while avoiding the potential pitfalls of early market…
Website: pureglobal.com

